Phenyl-substituted aminomethyl pyrrolidinone

Plain-language summaryIntrigue 30 / 100

Nebracetam is a phenyl-aminomethyl pyrrolidinone racetam developed in Japan. It is reported to enhance acetylcholine release through different mechanisms than other racetams. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Discontinued 1980s racetam with a real M1 twist but no active research community and better probes now available

Look, nebracetam is one of those 1980s Japanese pharma experiments that had a real idea behind it and then got quietly shelved. Daiichi took the piracetam scaffold, dropped a 4-phenyl group onto the pyrrolidinone ring (a structural move similar to phenylpiracetam), and added an aminomethyl modification that introduced something the classical racetams dont have: partial M1 muscarinic acetylcholine receptor agonism. That’s a legitimately different pharmacological profile. M1 selectivity has been a persistent goal in cholinergic CNS pharmacology, and nebracetam gets part of the way there without tipping into the full agonist territory that caused the older M1 programs so much trouble.

The problem is thats where the story peaks. The Phase 2 program in mild cognitive impairment and elderly memory disorders came back positive but modest, and Daiichi discontinued. We dont have a clean public record of exactly why. Was it effect size? A subtle safety signal at scale? Commercial calculus? That ambiguity is itself informative. Nobody has seriously revisited it since, and the absence of follow-on development from any group in four decades is a meaningful data point against it.

The M1 angle would be more compelling if better probes didn’t now exist. Xanomeline-trospium (Cobenfy) has defined what M1 selective agonism can do in a clinical context, and its mechanistic story is sharper than nebracetam’s partial activity. On the racetam side, phenylpiracetam handles the phenyl-substituted question with more accessible literature and a cleaner investigator community behind it. Nebracetam doesnt obviously beat either of those reference compounds on the bench.

The evidence quality is thin relative to its age. The Phase 2 data exists but was never published in a form thats independently verifiable or widely replicated. The Daiichi-era preclinical work is real but aging, and outside replication is sparse enough that this sits close to single-lab territory even though it technically cleared Phase 2. Thats not nothing, but its not a strong foundation for a 2026 research program.

We’d reach for nebracetam only if we were specifically trying to dissect the M1 component of racetam-class effects and had exhausted better options. That’s a narrow historical question. For modern muscarinic research the selective agonist literature is cleaner; for modern racetam research other analogs have more contemporary traction. Honestly, the score reflects its position accurately: interesting concept, real early clinical signal, discontinued program, no serious modern home.

Novelty: 22
Mechanism promise: 38
In-category differentiation: 22
Evidence quality: 33
Translational signal: 28
Research bench value: 25

Rationale Nebracetam has a genuinely distinct profile from classical racetams via partial M1 muscarinic agonist activity, which is the one thing that makes it interesting, but development was discontinued after modest Phase 2 results and no serious external group has picked it up since. Both the muscarinic and the phenyl-racetam questions it was positioned to answer are now better addressed by other compounds.

Phenyl-substituted aminomethyl pyrrolidinone

A 4-phenyl-pyrrolidinone with M1 muscarinic receptor agonist activity developed by Daiichi for cognitive impairment, discontinued in development.

Abstract

Nebracetam (WEB-1881-FU; 4-phenyl-2-pyrrolidinone-1-acetamide methyl derivative; CAS 97205-34-0; molecular formula C13H18N2O2; molecular weight 234.30) is a piracetam analog developed by Daiichi Pharmaceutical in Japan in the 1980s with structural features distinct from the classical racetam class. The compound includes a 4-phenyl group on the pyrrolidinone ring (similar to phenylpiracetam) and an aminomethyl modification on the acetamide side chain. Pharmacology shows partial M1 muscarinic acetylcholine receptor agonist activity in addition to the cholinergic facilitation typical of the racetam class. Phase 2 trials in mild cognitive impairment and elderly memory disorders showed positive but modest results; the development program was discontinued and the compound was never approved. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled. Pharmacokinetics include plasma half-life of approximately 4 hours and good oral bioavailability. The clinical evidence base is limited; the M1 muscarinic agonist activity introduces a distinct profile from the open-chain racetams.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-038Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Phenyl-substituted aminomethyl pyrrolidinone

Nebracetam

Abstract

Read the full monograph